Recent Analyst Ratings for CG Oncology Inc.
Date | Price Target | Rating | Analyst |
---|---|---|---|
1/7/2025 | Buy | TD Cowen | |
10/24/2024 | $60.00 | Buy | UBS |
9/23/2024 | $66.00 | Outperform | RBC Capital Mkts |
8/28/2024 | $65.00 | Buy | ROTH MKM |
6/28/2024 | $65.00 | Buy | BofA Securities |
2/20/2024 | $75.00 | Overweight | Cantor Fitzgerald |
2/20/2024 | $42.00 | Neutral | Goldman |
2/20/2024 | $55.00 | Overweight | Morgan Stanley |
CG Oncology Inc. Press Releases
Fastest customizable press release news feed in the world
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS
Cretostimogene Grenadenorepvec Data Continues to Demonstrate Best-in-Class Durability of Response as well as Consistent and Compelling Safety and Efficacy
– Latest BOND-003 data show 75.5% of patients achieved a complete response at any time –– Median duration of response exceeds 28 months and is ongoing –– No close contact precautions needed post cretostimogene treatment – IRVINE, Calif., March 24, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that 83 out of 110 patients (75.5%) achieved a complete response (CR) at any time in a Phase 3 study of cretostimogene monotherapy for high-risk BCG-unresponsive non-muscle invasive bladder cancer wit
CG Oncology to Participate in the 40th Annual European Association of Urology Congress with a Series of Key Presentations and Updates
IRVINE, Calif., March 12, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that a late-breaking abstract on BOND-003 Cohort C, as well as three posters highlighting cretostimogene grenadenorepvec, will be presented at the 40th Annual European Association of Urology (EAU) Congress taking place in Madrid, Spain, from March 21-24, 2025. The Annual EAU Congress is Europe's biggest urological event, where thousands of healthcare professionals from around the world gather to present research and learn
CG Oncology to Present at the TD Cowen 45th Annual Health Care Conference
IRVINE, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to present at the TD Cowen 45th Annual Health Care Conference in Boston, MA on Wednesday, March 5, 2025, at 11:10 am ET. Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live
CG Oncology Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares
IRVINE, Calif., Dec. 16, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the closing of its public offering of 9,200,000 shares of its common stock, 8,500,000 of which were offered by CG Oncology, which includes the exercise in full by the underwriters of their option to purchase 1,200,000 additional shares, and 700,000 of which were offered by an existing stockholder of CG Oncology, each at a public offering price of $28.00 per share. The gross proceeds to CG Oncology from the offeri
CG Oncology Announces Pricing of Public Offering
IRVINE, Calif., Dec. 12, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced the pricing of its public offering of 8,000,000 shares of its common stock, 7,300,000 of which are being offered by CG Oncology and 700,000 of which are being offered by an existing stockholder of CG Oncology, each at a public offering price of $28.00 per share. The gross proceeds to CG Oncology from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to
CG Oncology Announces Proposed Public Offering
IRVINE, Calif., Dec. 11, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 7,300,000 shares of its common stock. Additionally, an existing stockholder of CG Oncology intends to offer and sell 700,000 shares of CG Oncology's common stock in the proposed offering. CG Oncology will not receive proceeds from the sale of the shar
SUO-CTC and CG Oncology Announce the First Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award
SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the first annual CG-SUO-CTC NMIBC Research Fellowship designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladde
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
– 74.5% of patients achieved a complete response at any time – – Median duration of response is greater than 27 months and not reached – – Latest data update continued to show favorable safety and tolerability results – – Company hosting virtual investor event with lead investigator at 8 am EST today – IRVINE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unr
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 7 am CST on December 5, 2024, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In addition to company executives, this call will feature Mark Tyson, II, M.D., M.P.H., urologic oncologist at Mayo Clinic, and lead investigator in the BOND-003 study. Dr. Tyson is presenti
CG Oncology Inc. Analyst Ratings
Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.
TD Cowen initiated coverage on CG Oncology
TD Cowen initiated coverage of CG Oncology with a rating of Buy
UBS initiated coverage on CG Oncology with a new price target
UBS initiated coverage of CG Oncology with a rating of Buy and set a new price target of $60.00
RBC Capital Mkts initiated coverage on CG Oncology with a new price target
RBC Capital Mkts initiated coverage of CG Oncology with a rating of Outperform and set a new price target of $66.00
ROTH MKM initiated coverage on CG Oncology with a new price target
ROTH MKM initiated coverage of CG Oncology with a rating of Buy and set a new price target of $65.00
BofA Securities initiated coverage on CG Oncology with a new price target
BofA Securities initiated coverage of CG Oncology with a rating of Buy and set a new price target of $65.00
Cantor Fitzgerald initiated coverage on CG Oncology with a new price target
Cantor Fitzgerald initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $75.00
Goldman initiated coverage on CG Oncology with a new price target
Goldman initiated coverage of CG Oncology with a rating of Neutral and set a new price target of $42.00
Morgan Stanley initiated coverage on CG Oncology with a new price target
Morgan Stanley initiated coverage of CG Oncology with a rating of Overweight and set a new price target of $55.00
CG Oncology Inc. Insider Purchases
Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.
Decheng Capital Global Life Sciences Fund Iv, L.P. bought $7,600,000 worth of shares (400,000 units at $19.00) (SEC Form 4) (Amendment)
4/A - CG Oncology, Inc. (0001991792) (Issuer)
CG Oncology Inc. Insider Trading
Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.
Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $28,000 worth of shares (1,000 units at $28.00) (SEC Form 4)
4 - CG Oncology, Inc. (0001991792) (Issuer)
Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $28,610 worth of shares (1,000 units at $28.61) (SEC Form 4)
4 - CG Oncology, Inc. (0001991792) (Issuer)
Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $29,660 worth of shares (1,000 units at $29.66) (SEC Form 4)
4 - CG Oncology, Inc. (0001991792) (Issuer)
Director Song Hong Fang sold $19,600,000 worth of shares (700,000 units at $28.00) (SEC Form 4)
4 - CG Oncology, Inc. (0001991792) (Issuer)
Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $28,840 worth of shares (1,000 units at $28.84) (SEC Form 4)
4 - CG Oncology, Inc. (0001991792) (Issuer)
Director Post Leonard E exercised 1,000 shares at a strike of $0.60 and sold $34,542 worth of shares (1,000 units at $34.54) (SEC Form 4)
4 - CG Oncology, Inc. (0001991792) (Issuer)
SEC Form 4 filed by CFO Roche Corleen M.
4 - CG Oncology, Inc. (0001991792) (Issuer)
SEC Form 4 filed by Director Post Leonard E
4 - CG Oncology, Inc. (0001991792) (Issuer)
SEC Form 4 filed by Director Graf Susan E
4 - CG Oncology, Inc. (0001991792) (Issuer)
SEC Form 4 filed by Director Liu Brian Guan-Chyun
4 - CG Oncology, Inc. (0001991792) (Issuer)
CG Oncology Inc. SEC Filings
SEC Form S-3ASR filed by CG Oncology Inc.
S-3ASR - CG Oncology, Inc. (0001991792) (Filer)
SEC Form 10-K filed by CG Oncology Inc.
10-K - CG Oncology, Inc. (0001991792) (Filer)
CG Oncology Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
8-K - CG Oncology, Inc. (0001991792) (Filer)
CG Oncology Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
8-K - CG Oncology, Inc. (0001991792) (Filer)
SEC Form 144 filed by CG Oncology Inc.
144 - CG Oncology, Inc. (0001991792) (Subject)
Amendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.
SCHEDULE 13G/A - CG Oncology, Inc. (0001991792) (Subject)
Amendment: SEC Form SCHEDULE 13G/A filed by CG Oncology Inc.
SCHEDULE 13G/A - CG Oncology, Inc. (0001991792) (Subject)
CG Oncology Inc. filed SEC Form 8-K: Leadership Update
8-K - CG Oncology, Inc. (0001991792) (Filer)
SEC Form 424B4 filed by CG Oncology Inc.
424B4 - CG Oncology, Inc. (0001991792) (Filer)
SEC Form EFFECT filed by CG Oncology Inc.
EFFECT - CG Oncology, Inc. (0001991792) (Filer)
CG Oncology Inc. Financials
Live finance-specific insights
CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates
- Cretostimogene Monotherapy Demonstrated Sustained, Durable Complete Responses in High-Risk Bacillus Calmette Guérin (BCG)-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) - - Initiated CORE-008 Clinical Trial of Cretostimogene Monotherapy in High-Risk BCG-Naïve (Cohort A) and BCG-Exposed (Cohort B) NMIBC - - Late-Breaking Clinical and First Translational Data from BOND-003 Cohort C Presented at the 40th Annual European Association of Urology Congress - - Completed Oversubscribed $238 Million Follow-on Public Equity Offering that Extends Expected Runway into the First Half of 2028 - IRVINE, Calif., March 28, 2025 (GLOBE NEWS
Groundbreaking Cretostimogene Grenadenorepvec Monotherapy Data Demonstrates Sustained, Durable Complete Responses in High-Risk BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
– 74.5% of patients achieved a complete response at any time – – Median duration of response is greater than 27 months and not reached – – Latest data update continued to show favorable safety and tolerability results – – Company hosting virtual investor event with lead investigator at 8 am EST today – IRVINE, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced topline data from the Phase 3 BOND-003 trial in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unr
CG Oncology to Host Conference Call and Webcast on BOND-003 Data on Thursday, December 5, 2024
IRVINE, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ:CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced it will host a conference call and live webcast at 7 am CST on December 5, 2024, to discuss results from the Phase 3 BOND-003 trial of cretostimogene monotherapy in high-risk BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). In addition to company executives, this call will feature Mark Tyson, II, M.D., M.P.H., urologic oncologist at Mayo Clinic, and lead investigator in the BOND-003 study. Dr. Tyson is presenti
Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer
- Phase 3 BOND-003 study results showed sustained, durable complete responses over 12 months with novel investigational oncolytic immunotherapy - - Company will hold an investor conference call today at 4:30pm EDT - IRVINE, Calif., May 03, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. today announced that data from the Phase 3 BOND-003 study evaluating the efficacy and safety of cretostimogene monotherapy in patients with high-risk Non-Muscle Invasive Bladder Cancer (NMIBC) unresponsive to Bacillus Calmette Guerin (BCG), showed that 75.2% of patients (79 out of 105 [95% confidence interval (CI), 65-83]) achieved a complete response (CR) at any time, as of the cutoff date of April 1, 202
CG Oncology Inc. Large Ownership Changes
This live feed shows all institutional transactions in real time.
Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.
SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)
Amendment: SEC Form SC 13G/A filed by CG Oncology Inc.
SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)
SEC Form SC 13G filed by CG Oncology Inc.
SC 13G - CG Oncology, Inc. (0001991792) (Subject)
SEC Form SC 13G/A filed by CG Oncology Inc. (Amendment)
SC 13G/A - CG Oncology, Inc. (0001991792) (Subject)
SEC Form SC 13G filed by CG Oncology Inc.
SC 13G - CG Oncology, Inc. (0001991792) (Subject)